New directions and evolving challenges in the CAR-T cell therapy space

Cell & Gene Therapy Insights 2023; 9(3), 187–193

DOI: 10.18609/cgti.2023.027

Published: 8 March
Amir Hefni, David Kuzan

Roisin McGuigan, Editor, BioInsightstalks to Amir Hefni, Global Head, Cell & Gene Therapies, and David Kuzan, Global Medical Head, Cell & Gene Therapies, Novartis

Amir Hefni is the Global Head for Cell & Gene Therapy at Novartis. He currently leads the development and implementation of the Global C&G strategy across indications and disease areas. Amir joined Novartis from Ipsen, where he was Global Asset Head, Oncology and led the launch of multiple indications across the globe as well as drove a rich Life Cycle Management program. Previously, he was with Bristol-Myers Squibb (BMS) for 11 years, roles included leading thoracic indications for US Oncology (NSCLC, SCLC, and SCCHN). Furthermore, Amir brings a wealth of experience working across different countries including US, UK/Ireland and Sweden. Amir holds a BSc and PhD in Immuno-Pharmacology from King’s College London, University of London (UK) and a MBA from Warwick Business School, University of Warwick (UK).

David Kuzan is the Global Medical Head for Cell & Gene Therapy at Novartis accountable for development and execution of C&G medical strategy across global, region and country and execution of the medical affairs program for the C&G pipeline. David holds a Masters in Middle Eastern Politics, a Masters in Physiological Sciences, a medical degree from the University of Oxford and a Diploma in Pharmaceutical Medicine.